Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population pharmacokinetics and exposure-response of albinterferon alfa-2b.

Journal of clinical pharmacology - 1 Apr 2012

Riggs Matthew M, Bergsma Timothy T, Rogers James A, Gastonguay Marc R, Subramanian G Mani, Chen Cecil, Devalaraja Matt, Corey Alfred E, Sun Haiying, Yu Jing, Stein Daniel S

Abstract excerpt

Albinterferon alfa-2b (albIFN) has been studied for treatment of chronic hepatitis C virus (HCV). A population pharmacokinetics model was developed using nonlinear mixed-effects modeling. Efficacy/safety exposure-response relationships were assessed for subcutaneous albIFN doses (900-1800 µg once every 2 or 4 weeks) administered for either 24 weeks (HCV genotypes 2/3) or 48 weeks (genotype 1), plus daily oral...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Albumins
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Injections, Subcutaneous

Share to Interferon-alpha

Share to Logistic Models

Share to Ribavirin

Share to Tissue Distribution

Source

Identifiers

PMID: 21551316
DOI: 10.1177/0091270011399576

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population pharmacokinetics and exposure-response of albinterferon alfa-2b.PMID 21551316Read ↗

Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.Semantic proximity Read ↗

Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3.Semantic proximity Read ↗

Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients.Semantic proximity Read ↗

Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C.Semantic proximity Read ↗

Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients.Semantic proximity Read ↗

Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.Semantic proximity Read ↗

A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients.Semantic proximity Read ↗

Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 2: Exposure-response analyses for efficacy and safety variables.Semantic proximity Read ↗

Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates.Semantic proximity Read ↗

Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C.Semantic proximity Read ↗

Population Pharmacokinetic Analysis of Yimitasvir in Chinese Healthy Volunteers and Patients with Chronic Hepatitis C Virus InfectionSemantic proximity Read ↗

Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.